Procter & Gamble Health credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY27Jun 2026FY26Jun 2025FY25Jun 2024FY24Jun 2023FY23 and earlierAlpha Plus
——−244−440
FY23 and earlierEvery year the company has filed comes with Alpha Plus.
——−0.45×−0.59×
——−0.80×−1.36×
668.43×707.50×386.94×385.17×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PGHL₹5,513.50

Procter & Gamble Health Limited

· Pharma & Health
₹ CrorePeersSANOFICONRSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCASTRAZENMcap ₹9,152 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
30/06/2023
FY25
30/06/2024
FY26
30/06/2025
FY27
30/06/2026
Net Debt-440.2-244.4——
Net Debt/Equity-0.59-0.45——
Net Debt/EBITDA-1.36-0.80——
Interest Coverage (EBIT/Interest)385.17386.94707.50668.43
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY27 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.